BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen YX, Zeng ZC, Tang ZY, Fan J, Zhou J, Jiang W, Zeng MS, Tan YS. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer 2010;10:492. [PMID: 20840777 DOI: 10.1186/1471-2407-10-492] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Keane FK, Hong TS. Role and Future Directions of External Beam Radiotherapy for Primary Liver Cancer. Cancer Control 2017;24:1073274817729242. [PMID: 28975835 DOI: 10.1177/1073274817729242] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
2 Jackson MW, Amini A, Jones BL, Rusthoven CG, Schefter TE, Goodman KA. Treatment Selection and Survival Outcomes With and Without Radiation for Unresectable, Localized Intrahepatic Cholangiocarcinoma. Cancer J 2016;22:237-42. [PMID: 27441741 DOI: 10.1097/PPO.0000000000000213] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
3 Rahnemai-Azar AA, Pandey P, Kamel I, Pawlik TM. Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection. Hepat Oncol 2016;3:223-39. [PMID: 30191045 DOI: 10.2217/hep-2016-0009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
4 Kamarajah S, Giovinazzo F, Roberts KJ, Punia P, Sutcliffe RP, Marudanayagam R, Chatzizacharias N, Isaac J, Mirza DF, Muiesan P, Dasari BV. The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: Review of literature and pooled analysis. Ann Hepatobiliary Pancreat Surg. 2020;24:6-16. [PMID: 32181423 DOI: 10.14701/ahbps.2020.24.1.6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Kasuya G, Terashima K, Shibuya K, Toyama S, Ebner DK, Tsuji H, Okimoto T, Ohno T, Shioyama Y, Nakano T, Kamada T; Japan Carbon-Ion Radiation Oncology Study Group. Carbon-ion radiotherapy for cholangiocarcinoma: a multi-institutional study by and the Japan carbon-ion radiation oncology study group (J-CROS). Oncotarget 2019;10:4369-79. [PMID: 31320991 DOI: 10.18632/oncotarget.27028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
6 Entezari P, Riaz A. Intrahepatic Cholangiocarcinoma.Semin Intervent Radiol. 2020;37:475-483. [PMID: 33328703 DOI: 10.1055/s-0040-1719188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jung DH, Kim MS, Cho CK, Yoo HJ, Jang WI, Seo YS, Paik EK, Kim KB, Han CJ, Kim SB. Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma. Radiat Oncol J. 2014;32:163-169. [PMID: 25324988 DOI: 10.3857/roj.2014.32.3.163] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
8 Dover LL, Oster RA, McDonald AM, DuBay DA, Wang TN, Jacob R. Impact of adjuvant chemoradiation on survival in patients with resectable cholangiocarcinoma. HPB (Oxford) 2016;18:843-50. [PMID: 27542590 DOI: 10.1016/j.hpb.2016.07.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
9 Cho Y, Kim TH, Seong J. Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma. Strahlenther Onkol 2017;193:620-9. [PMID: 28424838 DOI: 10.1007/s00066-017-1128-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
10 Zheng X, Chen B, Wu JX, Jia AY, Rong WQ, Wang LM, Wu F, Zhao YT, Li YX, Wang WH. Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic cholangiocarcinoma that adhere to major vessels. Cancer Manag Res 2018;10:3973-81. [PMID: 30310318 DOI: 10.2147/CMAR.S172940] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Le VH, O'Connor VV, Li D, Melstrom LG, Fong Y, DiFronzo AL. Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate. J Surg Oncol 2021;123:164-71. [PMID: 32974932 DOI: 10.1002/jso.26230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
12 Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016;34:460-468. [PMID: 26668346 DOI: 10.1200/jco.2015.64.2710] [Cited by in Crossref: 209] [Cited by in F6Publishing: 105] [Article Influence: 34.8] [Reference Citation Analysis]
13 Kingham TP, Aveson VG, Wei AC, Castellanos JA, Allen PJ, Nussbaum DP, Hu Y, D'Angelica MI. Surgical management of biliary malignancy. Curr Probl Surg 2021;58:100854. [PMID: 33531120 DOI: 10.1016/j.cpsurg.2020.100854] [Reference Citation Analysis]
14 Das P, Abboud MT, Haque W, Javle M, Kaseb A, Curley SA, Vauthey JN, Aloia TA, Beddar AS, Delclos ME, Krishnan S, Crane CH. Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. Pract Radiat Oncol 2013;3:344-8. [PMID: 24674408 DOI: 10.1016/j.prro.2012.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Isohashi F, Ogawa K, Oikawa H, Onishi H, Uchida N, Maebayashi T, Kanesaka N, Tamamoto T, Asakura H, Kosugi T, Uno T, Ito Y, Karasawa K, Takayama M, Manabe Y, Yamazaki H, Takemoto M, Yoshioka Y, Nemoto K, Nishimura Y; Japanese Radiation Oncology study Group (JROSG). Patterns of radiotherapy practice for biliary tract cancer in Japan: results of the Japanese radiation oncology study group (JROSG) survey. Radiat Oncol 2013;8:76. [PMID: 23547715 DOI: 10.1186/1748-717X-8-76] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
16 Moureau-Zabotto L, Turrini O, Resbeut M, Raoul JL, Giovannini M, Poizat F, Piana G, Delpero JR, Bertucci F. Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma. BMC Cancer 2013;13:568. [PMID: 24299517 DOI: 10.1186/1471-2407-13-568] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
17 Amini N, Ejaz A, Spolverato G, Kim Y, Herman JM, Pawlik TM. Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol 2014;110:163-70. [PMID: 24676600 DOI: 10.1002/jso.23605] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
18 Sebastian NT, Tan Y, Miller ED, Williams TM, Alexandra Diaz D. Stereotactic body radiation therapy is associated with improved overall survival compared to chemoradiation or radioembolization in the treatment of unresectable intrahepatic cholangiocarcinoma. Clin Transl Radiat Oncol 2019;19:66-71. [PMID: 31517072 DOI: 10.1016/j.ctro.2019.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, Geschwind JF, Pawlik TM. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013;217:736-750.e4. [PMID: 23890842 DOI: 10.1016/j.jamcollsurg.2013.05.021] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 10.4] [Reference Citation Analysis]
20 Kim YI, Park JW, Kim BH, Woo SM, Kim TH, Koh YH, Lee WJ, Kim CM. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol. 2013;8:292. [PMID: 24359879 DOI: 10.1186/1748-717x-8-292] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
21 Ho J, Curley SA. Diagnosis and Management of Intrahepatic and Extrahepatic Cholangiocarcinoma. Cancer Treat Res 2016;168:121-63. [PMID: 29206368 DOI: 10.1007/978-3-319-34244-3_7] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
22 Shen ZT, Zhou H, Li AM, Li B, Shen JS, Zhu XX. Clinical outcomes and prognostic factors of stereotactic body radiation therapy for intrahepatic cholangiocarcinoma. Oncotarget. 2017;8:93541-93550. [PMID: 29212171 DOI: 10.18632/oncotarget.19972] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
23 Högberg J, Rizell M, Hultborn R, Svensson J, Henrikson O, Mölne J, Gjertsson P, Bernhardt P. Heterogeneity of microsphere distribution in resected liver and tumour tissue following selective intrahepatic radiotherapy. EJNMMI Res 2014;4:48. [PMID: 26116112 DOI: 10.1186/s13550-014-0048-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
24 Rahnemai-Azar AA, Weisbrod AB, Dillhoff M, Schmidt C, Pawlik TM. Intrahepatic cholangiocarcinoma: current management and emerging therapies. Expert Rev Gastroenterol Hepatol 2017;11:439-49. [PMID: 28317403 DOI: 10.1080/17474124.2017.1309290] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
25 Simo KA, Halpin LE, Mcbrier NM, Hessey JA, Baker E, Ross S, Swan RZ, Iannitti DA, Martinie JB. Multimodality treatment of intrahepatic cholangiocarcinoma: A review: Multimodality Therapy of iCCA. J Surg Oncol 2016;113:62-83. [DOI: 10.1002/jso.24093] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
26 Chen YX, Zeng ZC, Tang ZY, Fan J, Zhou J, Jiang W, Zeng MS, Tan YS. Prediction of the lymph node status in patients with intrahepatic cholangiocarcinoma: analysis of 320 surgical cases. Front Oncol. 2011;1:42. [PMID: 22649763 DOI: 10.3389/fonc.2011.00042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
27 Chopra S, Mathew AS, Engineer R, Shrivastava SK. Positioning high-dose radiation in multidisciplinary management of unresectable cholangiocarcinomas: review of current evidence. Indian J Gastroenterol 2014;33:401-7. [PMID: 25135161 DOI: 10.1007/s12664-014-0495-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 95] [Article Influence: 21.6] [Reference Citation Analysis]
29 Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268-1289. [PMID: 24681130 DOI: 10.1016/j.jhep.2014.01.021] [Cited by in Crossref: 618] [Cited by in F6Publishing: 641] [Article Influence: 88.3] [Reference Citation Analysis]
30 Niska JR, Keane FK, Wolfgang JA, Hahn PF, Wo JY, Zhu AX, Hong TS. Impact of intravenous contrast enhancement phase on target definition for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC): Observations from patients enrolled on a prospective phase 2 trial. Pract Radiat Oncol 2016;6:e9-16. [PMID: 26598907 DOI: 10.1016/j.prro.2015.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
31 Mejia JC, Pasko J. Primary Liver Cancers: Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Clin North Am 2020;100:535-49. [PMID: 32402299 DOI: 10.1016/j.suc.2020.02.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
32 Fiorentino A, Gregucci F, Desideri I, Fiore M, Marino L, Errico A, Di Rito A, Borghetti P, Franco P, Greto D, Donato V. Radiation treatment for adult rare cancers: Oldest and newest indication. Crit Rev Oncol Hematol 2021;159:103228. [PMID: 33508447 DOI: 10.1016/j.critrevonc.2021.103228] [Reference Citation Analysis]
33 Yoh T, Hatano E, Yamanaka K, Nishio T, Seo S, Taura K, Yasuchika K, Okajima H, Kaido T, Uemoto S. Is Surgical Resection Justified for Advanced Intrahepatic Cholangiocarcinoma? Liver Cancer 2016;5:280-9. [PMID: 27781200 DOI: 10.1159/000449339] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
34 Keane FK, Zhu AX, Hong TS. Radiotherapy for Biliary Tract Cancers. Seminars in Radiation Oncology 2018;28:342-50. [DOI: 10.1016/j.semradonc.2018.06.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
35 Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, Fauchart JP, Martin P, Bennouna J, Morin T, Bonnet I, Maingon P, Lepage C, Chauffert B. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. Eur J Cancer 2014;50:2975-82. [PMID: 25241229 DOI: 10.1016/j.ejca.2014.08.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
36 Boimel PJ, Binder KR, Hong TS, Feng M, Ben-Josef E. Cholangiocarcinoma and Gallbladder Cases: An Expert Panel Case-Based Discussion. Semin Radiat Oncol 2018;28:351-61. [PMID: 30309645 DOI: 10.1016/j.semradonc.2018.06.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
37 Liu M, Lo C, Lin C, Chao H, Yang J, Lin K, Fan C, Su Y, Huang W. Stereotactic Ablative Radiotherapy for Patients with Unresectable or Medically Inoperable Cholangiocarcinoma. Tumori 2017;103:236-41. [DOI: 10.5301/tj.5000588] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Hung SP, Huang BS, Hsieh CE, Lee CH, Tsang NM, Chang JT, Chen JS, Chou WC, Tseng JH, Hong JH. Clinical Outcomes of Patients With Unresectable Cholangiocarcinoma Treated With Proton Beam Therapy. Am J Clin Oncol 2020;43:180-6. [PMID: 31764017 DOI: 10.1097/COC.0000000000000646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
39 Nguyen NA, Timotin E, Hunter R, Sur RK. High-dose rate intraluminal brachytherapy: An effective palliation for cholangiocarcinoma causing bile duct obstruction. Surgical Oncology 2018;27:625-9. [DOI: 10.1016/j.suronc.2018.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
40 Patel T. Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8:189-200. [PMID: 21460876 DOI: 10.1038/nrgastro.2011.20] [Cited by in Crossref: 204] [Cited by in F6Publishing: 243] [Article Influence: 20.4] [Reference Citation Analysis]
41 Lee J, Yoon WS, Koom WS, Rim CH. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol 2019;195:93-102. [DOI: 10.1007/s00066-018-1367-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
42 Sur MD, In H, Sharpe SM, Baker MS, Weichselbaum RR, Talamonti MS, Posner MC. Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 2015;22:2209-17. [PMID: 25476031 DOI: 10.1245/s10434-014-4275-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
43 Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanick CW, Koay EJ, Thames HD, Hong TS, Das P, Crane CH. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol 2016;34:219-26. [PMID: 26503201 DOI: 10.1200/JCO.2015.61.3778] [Cited by in Crossref: 121] [Cited by in F6Publishing: 59] [Article Influence: 20.2] [Reference Citation Analysis]
44 Zhou N, Hu A, Shi Z, Wang X, Zhu Q, Zhou Q, Ma J, Zhao F, Kong W, He J. Inter-observer agreement of computed tomography and magnetic resonance imaging on gross tumor volume delineation of intrahepatic cholangiocarcinoma: an initial study. Quant Imaging Med Surg 2021;11:579-85. [PMID: 33532258 DOI: 10.21037/qims-19-1093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Shao F, Qi W, Meng FT, Qiu L, Huang Q. Role of palliative radiotherapy in unresectable intrahepatic cholangiocarcinoma: population-based analysis with propensity score matching. Cancer Manag Res 2018;10:1497-506. [PMID: 29942151 DOI: 10.2147/CMAR.S160680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
46 Verma V, Kusi Appiah A, Lautenschlaeger T, Adeberg S, Simone CB 2nd, Lin C. Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base. J Gastrointest Oncol 2018;9:527-35. [PMID: 29998018 DOI: 10.21037/jgo.2018.01.15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
47 Aitken K, Hawkins M. The Role of Radiotherapy and Chemoradiation in the Management of Primary Liver Tumours. Clinical Oncology 2014;26:569-80. [DOI: 10.1016/j.clon.2014.05.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
48 Yu Q, Liu C, Pillai A, Ahmed O. Twenty Years of Radiation Therapy of Unresectable Intrahepatic Cholangiocarinoma: Internal or External? A Systematic Review and Meta-Analysis. Liver Cancer 2021;10:433-50. [PMID: 34721506 DOI: 10.1159/000516880] [Reference Citation Analysis]